Home › NDC Lookup › J-codes › J2783
J2783

J2783 – Injection, rasburicase, 0.5 mg · NDC Crosswalk & Billing Units

HCPCS Level II J-code · Medicare Part B drug billing
J-code ● 2 NDCs crosswalked per 0.5 MG $387.453/unit ASP+6%

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

📋 J2783 summary

J2783 is a HCPCS Level II J-code used to bill rasburicase, 0.5 mg, billed per 0.5 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.

Brand names associated with J2783: Elitek

Code J2783 Billing unit 0.5 MG Payment limit $387.453/unit NDC-Crosswalk 2 Quarter Q3 2026 RxCUI Atlas Trace the drug concept →

⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.

🗂️ Key billing facts

HCPCS codeJ2783
DescriptorInjection, rasburicase, 0.5 mg
Billing unit0.5 MG
Payment limit / unit$387.453
Est. ASP / unit$365.522 est.
Mapped NDCs2
Data periodQ3 2026
Last updated2026-08-20

🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026

📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$387.453
Est. ASP / unit
$365.522 est.
Est. after 2% sequester
$379.704
HCPCS dosage
0.5 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, rasburicase, 0.5 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1E
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2004-01-01
Date added2004-01-01
Source: CMS HCPCS Level II code file (imported via admin).

🧮 Dosing & billing-units calculator HCPCS UNITS

One billing unit of J2783 = 0.5 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.

🔁 NDCs that bill under J2783 WITH EST. MEDICARE PAY

2 NDCs map to J2783. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($387.453/unit) × that package's bill units.
NDC (11-digit)DrugLabelerPackageStrength Bill units Est. pay / pkg NADAC / unit StatusSource
00024-5150-10 Elitek rasburicase KIT Sanofi-Aventis 3 KIT in 1 CARTON (0024-5150-10) / 1 KIT... — 9 $3,487.08 — ● Active CMS + PDAC
00024-5151-75 Elitek rasburicase KIT Sanofi-Aventis 1 KIT in 1 CARTON (0024-5151-75) * 5 mL... — 15 $5,811.80 — ● Active CMS + PDAC
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.

📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)

Period
Total Part B spend
$1.99M
Claims
468
Beneficiaries
375
Spend / beneficiary
$5,297.55
Spend / claim
$4,244.83
Trend by period
Where J2783 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #324 of 824
#319 WOUND MATRIX Q4102 $2.16M #320 PURAPLY XT 1 SQ CM** Q4197 $2.14M #321 BKEMV Q5152 $2.1M #322 GAMIFANT J9210 $2.03M #323 HYPERRAB 90375 $2M #324 ELITEK J2783 $1.99M #325 OMVOH PEN* J2267 $1.94M #326 BIZENGRI J9382 $1.93M #327 THERASKIN** Q4121 $1.88M #328 ADYNOVATE J7207 $1.87M #329 ELFABRIO J2508 $1.79M
Total claims — #466 of 824
#461 IMAAVY J9256 487 #462 NEXVIAZYME J0219 481 #463 LIDOCAINE HCL IN 5%... J2002 477 #464 VINORELBINE TARTRATE J9390 477 #465 VPRIV J3385 474 #466 ELITEK J2783 468 #467 ARSENIC TRIOXIDE* J9017 453 #468 CYCLOPHOSPHAMIDE(J90... J9074 432 #469 MOZOBIL* J2562 424 #470 ADVATE* J7192 424 #471 DEMEROL* J2175 408

Full breakdown by period (2)
PeriodTotal spendBeneficiariesClaims$/beneficiary$/claim
2026 (Q1) $1.99M 375 468 $5,297.55 $4,244.83
2025 (Q1-Q4) $10.71M 1,523 2,227 $7,032.67 $4,809.50
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.

📈 Medicare Part B claims detail CMS PSPS · 2024

Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$6.61M
Medicare paid
$5.18M
Submitted services
18,943
Denial rate
4.6%
Allowed / service
$365.75
Submitted charges
$14.67M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.

🗺️ Where J2783 is utilized

⏳
The geographic utilization map is building for this code — it aggregates millions of CMS Part B claim lines, then caches the result. Refresh in a moment; if it doesn’t appear, this code may have no reportable Part B utilization.

📊 What bills under J2783

J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.

NDC products by ingredient
rasburicase 6
NDC products by labeler
Sanofi-Aventis U.S. LLC 6

🗃️ Data sources & freshness

Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
2 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.

⚠️ Practical billing caveats

  • A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
  • Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
  • Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
  • Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
  • The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
  • Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.

❓ J2783 billing FAQ

What is HCPCS code J2783?
J2783 is a HCPCS Level II J-code used to bill Injection, rasburicase, 0.5 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J2783?
One unit of J2783 represents 0.5 MG. Report the number of units equal to the dose administered divided by 0.5 MG.
How many units of J2783 should I bill?
Divide the dose administered by the code's unit size (0.5 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J2783?
The Medicare Part B payment limit is $387.453 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $379.704 per unit. Payment limits are revised quarterly.
Which NDCs bill under J2783?
2 NDCs currently map to J2783 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J2783 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.